A recent clinical trial to compare two antibiotic regimens in people with COPD experiencing exacerbations proved that the combination therapy is more effective at killing harmful bacteria in the lungs. The trial led by a team of researchers at Haiphong University of Medicine and Pharmacy in Vietnam observed that the rates of bacterial eradication were higher in patients on the combination therapy than in those given single-antibiotic treatment (96.7% vs. 88.6%). Although there is no proper consensus on the best antibiotic regimen for this purpose, the researchers said in a paper published in BMC Infectious Diseases that the multi-drug therapy appeared significantly better at killing specific types of bacteria that are known to cause lung disease, such as Acinetobacter baumannii and Pseudomonas aeruginosa.